• Contemporary ClinicContemporary Clinic
  • OTC GuideOTC Guide
  • Pharmacy Times
  • PTCEPTCE
  • Pharmacist Moms GroupPharmacist Moms Group
News
All News
FDA Updates
Press Releases
Media
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conferences
Conference Coverage
Conference Listing
Publications
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
Clinical
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Events
Upcoming Events
Upcoming Webinars
CE
Resources
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
logo
Spotlight
Community/RetailHospitalOncologyPharmacy TechnicianStudent
Clinical Role
Community/RetailHospitalOncologyPharmacy TechnicianSpecialty PharmacyStudent
Clinical
CoronavirusBrain HealthCardiovascular HealthDermatologyDiabetesFluHeart FailureHepatitis/MASHImmunizationMigrainePneumococcalVitamins and Supplements
Supplement Spotlight
October 2023 Pharmacy Technician Edition
All News
FDA Updates
Press Releases
All Videos
Digital Detail
Independent Corner
Insights
Interviews
MEDcast
Medical World News
Microsites
Peer Exchange
Perfect Consult
Podcasts
Practice Pearls
Sponsored Webcast
Student Voices
Webinars/Webcasts
Conference Coverage
Conference Listing
Pharmacy Times
Pharmacy Practice in Focus: Oncology
Pharmacy Practice in Focus: Health Systems
Pharmacy Careers
All Publications
About the Publications
Author Submission
Submit to Pharmacy Practice in Focus: Oncology
Submit to Pharmacy Practice in Focus: Health Systems
Become a Peer Reviewer
Supplements & Featured Publications
503B Compounding Pharmacy
ADHD
Allergy
Alzheimer Disease
Anxiety
Asthma
Atopic Dermatitis
Biosimilars
Bipolar Disorder
Brain Health
Breast Cancer
C. Difficile
COPD
COVID-19
Cardiovascular Health
Cervical Cancer
Cholangiocarcinoma
Cholesterol
Chronic Kidney Disease
Chronic Lymphocytic Leukemia
Classical Hematology
Colorectal Cancer
Continuous Glucose Monitoring
Cough and Cold
Depression
Dermatology
Diabetes
Digestive Health
Dry Eye Disease
Epilepsy
Eye Care
Flu
Future of Pharmacy
Gastrointestinal Cancer
Gastrointestinal Health
Gout
HER2 Breast Cancer
HIV
Heart Failure
Hematology
Hepatitis/MASH
Immunization
Immuno-oncology
Immunoglobulins
Infectious Disease
Lung Cancer
Lymphoma
Macular Degeneration
Mental Health
Migraine
Movement Disorders
Multiple Myeloma
Multiple Sclerosis
Myelofibrosis
Neurology
Neutropenia
Osteoporosis
Ovarian Cancer
Pain Management
Parkinson Disease
Pediatrics
Pharmacy Heroes
Pharmacy Management
Pneumococcal
PrEP
Prostate Cancer
Psoriasis
Psoriatic Arthritis
Psychedelics
Reimbursement
Reproductive Health
Respiratory Syncytial Virus
Rheumatoid Arthritis
Schizophrenia
Shingles
Skin Cancer
Sleep
Travel Vaccines
Veterinary Pharmacy
Vitamins and Supplements
Weight Management
Women's Health
Upcoming Events
Upcoming Webinars
CE
Clinical Forum
Cou-Co
Educated Patient
Information for the Pharmacist
Interactive Tools
Partners
Sponsored
Whiteboards
Subscribe
Advertisement

CLINICAL ROLE -

Community/Retail
| Hospital
| Oncology
| Pharmacy Technician
| Student

Article

March 7, 2019

Patients Recommend Ways to Reduce Breast Cancer-Related Long-Term Cost Burden

Author(s):

Jennifer Barrett, Associate Editor

Patient-driven recommendations to reduce breast cancer-related economic burden could be key to shaping policies and interventions.

Breast cancer survivorship is often associated with a significant long-term economic burden, especially for those managing adverse effects, such as breast cancer-related lymphedema. Health care providers can play an important role in helping patients navigate the financial complexities of their care. Still, the cost burden often persists beyond initial diagnosis and can have devastating long-term effects.

A new study published in Cancer provides a patient perspective on potential approaches to addressing the cost-related toxicities of breast cancer treatment. Patient-driven recommendations included solutions that go beyond direct medical costs, including psychosocial costs, indirect costs, time costs, and nonmedical direct costs.

“Patients have first-hand experience in navigating insurance and seeking eligibility for programs to help mitigate economic burden,” the researchers wrote in the study. “Documenting patients’ experiences through qualitative analysis can provide key insights into how to reduce economic burden.”

For the study, 40 long-term breast cancer survivors were selected for a qualitative interview from May to September 2015. Most of the patients received chemotherapy (77%) and radiation (83%), while 25% received hormonal therapy. Of the patients who participated, 60% experienced breast cancer-related lymphedema.

Of the patients interviewed, 27 offered recommendations aimed at reducing economic burden. Many patients identified 4 major areas for improvement: insurance, supportive services and care, financial assistance, and protective policies.

Among the insurance challenges, common recommendations listed by patients included improvements in insurance navigation, quality of coverage, affordability of coverage, and access to lymphedema treatment.

One patient pointed to the expenses of garment supplies, such as wrappings and bandages, used to help self-manage lymphedema, which were not covered by insurance. She described forgoing self-management because of the cost.

“Although patients consistently suggested expanding what insurers cover, shifting costs back onto insurers may not be enough to reduce economic burden, especially if third-party payers find other ways to pass costs back to patients,” the study authors explained.

The researchers pointed to how coverage expansion for lymphedema services and treatment lowered patient out-of-pocket costs and related hospitalizations in 1 state, with a less than 0.1% effect on costs for insurance claims and less than 0.2 % effect on premiums after 10 years. However, widespread changes to insurance will require efforts made by patients, providers, insurers, state and federal policymakers, and the pharmaceutical industry, they wrote.

Secondly, patients suggested expanding supportive care and services, such as implementing support groups, expanding the availability of home care services, transportation programs, and domestic assistance.

Additionally, several respondents indicated the need for financial assistance, such as providing assistance for those above the poverty line, raising awareness about existing services, and financial counseling and planning. Patients noted that screening and referral to financial services during oncology visits early on in the cancer treatment process would be beneficial.

“Although physicians could provide a list of references for patients to seek financial counseling in their office, as patients suggested, this approach may increase their time costs,” the researchers wrote. “Therefore, automatic referral by the physician or by another member of the health care team to a program that is integrated within the health system may be more efficient.”

Lastly, protective policies surrounding employment and medical leave for women after breast cancer treatment was listed as a concern, as well. Redesigning these policies to better accommodate chronic disease needs could play a part in reducing the economic burden.

Overall, the researchers concluded that changes are needed to mitigate the rising out of pocket costs experienced by breast cancer survivors in the United States. Patient-driven recommendations provide insight into the needs of long-term cancer survivors beyond the direct medical expenses at the time of disease and can guide health care providers in efforts to ease their patients’ financial burden.

Reference

Dean LT, Moss SL, Rollinson SI, et al. Patient recommendations for reducing long-lasting economic burden after breast cancer. Cancer. March 6, 2019. https://doi.org/10.1002/cncr.32012

Related Videos
Pharmacist and patient in a retail/community pharmacy setting -- Image credit: Zamrznuti tonovi | stock.adobe.com
Menoapuse spelled with wooden blocks -- Image credit: loran4a | stock.adobe.com
Related Content
Advertisement
3D rendering of bispecific antibodies  in action | Image Credit: © Александр Михайлюк - stock.adobe.com
May 21st 2025

Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Blood sample vial testing MUC1 levels | Image Credit: © luchschenF - stock.adobe.com
May 21st 2025

Study Links MUC1-C to Estrogen Receptor Expression and Endocrine Resistance in HR+/HER2– Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Published: May 20th 2025 | Updated: May 20th 2025

Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

Alana Hippensteele, Lead Editor
Primary biliary cholangitis -- Image credit: iushakovsky | stock.adobe.com
May 20th 2025

Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients

Gillian McGovern, Associate Editor
Related Content
Advertisement
3D rendering of bispecific antibodies  in action | Image Credit: © Александр Михайлюк - stock.adobe.com
May 21st 2025

Zanidatamab Plus Chemotherapy Shows Promising Anti-Tumor Activity in Treatment of HER2-Mutated Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology podcast
May 19th 2025

Insights from a Pharmacy Times Peer Exchange: Real-World Outcomes and Supportive Care

Alexandra Gerlach, Associate Editor
Blood sample vial testing MUC1 levels | Image Credit: © luchschenF - stock.adobe.com
May 21st 2025

Study Links MUC1-C to Estrogen Receptor Expression and Endocrine Resistance in HR+/HER2– Breast Cancer

Alexandra Gerlach, Associate Editor
pharmacy focus oncology edition
May 12th 2025

Insights from a Pharmacy Times Peer Exchange: Emerging ADCs and Real-World Management

Alexandra Gerlach, Associate Editor
Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients
Published: May 20th 2025 | Updated: May 20th 2025

Glofit-GemOx in R/R DLBCL: FDA Advisory Committee Reviews STARGLO Phase 3 Results for Transplant-Ineligible Patients

Alana Hippensteele, Lead Editor
Primary biliary cholangitis -- Image credit: iushakovsky | stock.adobe.com
May 20th 2025

Linerixibat Significantly Improves PBC-Related Cholestatic Pruritus in Adult Patients

Gillian McGovern, Associate Editor
Consent Preferences
About Us
Clinical Forums
Advertise
Contact Us
Editorial Staff
Privacy Policy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.